Total
0
Shares
XPhyto Therapeutics subsidiary achieves research milestone
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Arch Biopartners (ARCH) is entering into an exclusive agreement with the University of Cincinnati to license new patent claims for its topical wound treatment
  • The treatment, AB569, is designed to prevent, treat and heal burn and blast wound infections
  • The treatment was designed at the University of Cincinnati
  • The agreement builds on the existing license of AB569 Arch Biopartners has with the University of Cincinnati
  • Arch Biopartners is up 2.40 per cent on the day, with shares of the company trading at C$1.28 at 11:01 am ET

Arch Biopartners (ARCH) is entering into an agreement to license new patent claims for its topical wound treatment.

The treatment, AB569, is designed to prevent, treat and heal burn and blast wound infections.

The treatment was designed at the University of Cincinnati.

It is meant to to target multi-drug resistant infections that are difficult to treat in the lungs, burn or blast wounds of soldiers, surgical incisions and diabetic skin ulcers.

The agreement builds on the existing license of AB569 that Arch Biopartners already has with the University of Cincinnati.

"With this new license, Arch now has a commercial path to develop the topical wound gel version of AB569 for clinical use. We look forward to exploring opportunities where Arch can support human trials targeting the prevention and treatment of antibiotic resistant infections in wounds," said Arch Biopartners CEO Richard Muruve.

Burn or blast injuries are a major cause of morbidity and mortality, especially in the military. In some cases this is due to sepsis, which is often preceded by wound infection that delays wound healing.

A significant challenge in treating bacterial infections is their inherent or acquired antibiotic resistance. AB569 has been shown to kill multi-drug resistant (MDR) Gram-negative (G-) bacteria, according to the company.

Bacterial infections have historically been a major clinical challenge for both military and civilian health professionals, especially during the Iraq and Afghanistan conflicts. In combat medical care, acquired wound, burn, blast and ventilator-associated pneumonia infections, represent a formidable multi-drug resistant (MDR-AB) pathogen.

Arch Biopartners is a clinical stage company focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. 

Arch Biopartners is up 2.40 per cent on the day, with shares of the company trading at C$1.28 at 11:01 am ET.

More From The Market Herald
Assure (TSXV:IOM) approved to list on NASDAQ Capital Market

" Assure (TSXV:IOM) approved to list on NASDAQ Capital Market

Assure Holdings (IOM) has been approved to list its shares on the NASDAQ Capital Market.
Levitee Labs - CEO, Pouya Farmand. - The Market Herald Canada

" Levitee Labs (CSE:LVT) announces DTC eligibility

Common shares of Levitee Labs (LVT) are now eligible to be electronically cleared and settled through the DTC.
Avicanna Inc - CEO, Aras Azadian - The Market Herald Canada

" Avicanna (TSX:AVCN) files US patent application for cannabinoid formulation

Avicanna (AVCN) has filed a provisional patent application with the United States Patent and Trademark Office.
Alpha Cognition (TSXV:ACOG) announces $12.5 million public offering

" Alpha Cognition (TSXV:ACOG) announces $12.5 million public offering

Alpha Cognition (ACOG) has announced a C$12.5 million public offering led by Raymond James.